Latest news with #SiemensHealthineers
Yahoo
3 days ago
- Business
- Yahoo
$46.5 Bn AI in Medical Diagnostics Market Opportunities and Strategies to 2034: Machine Learning and Computer Vision Set to Transform AI Diagnostics Landscape
Global AI in medical diagnostics market to surge from $1.92B in 2024 to $46.59B by 2034. Key growth drivers include aging population, rising healthcare expenditure, and tech innovations. Top players: Siemens Healthineers, Merative, Tempus Labs. Software to lead growth. Explore strategic insights. AI in Medical Diagnostics Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "AI in Medical Diagnostics Market Opportunities and Strategies to 2034" has been added to offering. The report on AI in medical diagnostics market highlights its historical and projected growth, analyzing regional trends and market dynamics from 2019 to 2034. The market, valued at $1.92 billion in 2024, is projected to soar to $46.59 billion by 2034, demonstrating a significant compound annual growth rate (CAGR) of 33.72% during the forecast period. Significant contributors to historical growth included rising demand for personalized medicine, increased adoption of cloud-based AI solutions, and the proliferation of chronic diseases. Despite this, challenges like ethical concerns and data protection issues posed barriers to expansion. Looking ahead, factors such as an aging global population, escalating healthcare expenditures, and supportive government measures are anticipated to propel market growth, although the high procurement costs could present hurdles. The market is dominated by key players, with Siemens Healthineers AG leading at an 11.10% market share in 2023. Other notable competitors include Merative L.P., Tempus Labs Inc., and Enlitic Inc. Geographically, North America remains the most significant market region, holding 41.12% of the 2024 market value, with Asia Pacific and the Middle East poised for the fastest growth in the coming years. By component, the software segment leads, representing 59.65% of the market in 2024 and projected to grow rapidly at a CAGR of 43.11%. Application-wise, computer-aided detection currently dominates the market, while computer-aided diagnosis is expected to expand fastest. Hospitals, as the primary end users, also represent the largest and fastest-growing segment by end-user category. In terms of technological segmentation, machine learning currently dominates, but computer vision is expected to see the quickest growth. The specialty segmentation identifies neurology as the largest segment, while radiology is set to experience rapid expansion. Emerging opportunities are identified in various segments, with the software segment anticipated to gain $5.73 billion by 2029. Similarly, hospitals, computer-aided detection, machine learning, and the neurology segment each present substantial revenue-generating potential. Trend-based strategies for market players emphasize optimizing operations through AI to enhance diagnostic accuracy and streamline workflows, ultimately boosting productivity and patient care. Advancements in radiology efficiency, innovations in vital sign monitoring, and personalized cancer therapies are highlighted. Engagement through strategic partnerships and sophisticated AI tools also play a pivotal role in shaping market dynamics. The report suggests specific strategies for AI medical diagnostics companies to capture market opportunities. These include optimizing AI for precision, enhancing radiology efficiency, and advancing healthcare workflows. Expanding into emerging markets, investing in innovative diagnostic tools, and maintaining competitive pricing are recommended approaches to thrive in the evolving landscape. Key Attributes: Report Attribute Details No. of Pages 315 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $1.92 Billion Forecasted Market Value (USD) by 2034 $46.59 Billion Compound Annual Growth Rate 37.6% Regions Covered Global Major Market Trends Utilizing AI to streamline medical operations and optimize care journeys across the healthcare system. Transforming healthcare efficiency with AI-driven radiology solutions for faster and more accurate results. Innovating healthcare workflows with AI to address clinician burnout and enhance productivity. Advancements in vital sign monitoring utilizing photoplethysmography and other sensor technologies. Enhancing personalized cancer therapies through AI-based biomarker identification. Launch of advanced diagnostics tools for detecting accurate and clinically reliable information. Integration of quantitative reporting in medical imaging for liver disease diagnosis. Increasing investments to revolutionize decision-making with personalized AI insights. Strategic partnerships and collaborations among major players. Market Segments Covered: Component: Software, Hardware, Services Application: Computer-Aided Detection, Diagnosis, Quantitative Analysis, Clinical Decision End User: Hospitals, Diagnostics Imaging Centers, Laboratories, Others Technology: NLP, Computer Vision, Machine Learning, Context-Aware Computing Specialty: Cardiology, Oncology, Pathology, Radiology, Chest and Lung, Neurology, Others Companies Featured Siemens Healthineers AG Merative L.P. Tempus Labs Inc. Enlitic Inc. GE Healthcare Technologies Inc. Microsoft Corporation Koninklijke Philips N.V. NVIDIA Corporation PathAI Inc. Aidoc Medical Ltd. Samsung Medison Co., Ltd. Wipro GE Healthcare Private Limited SK Telecom Healthians iHridAI InMed AI Olympus Corporation Anaut Inc. XtalPi Lunit Niramai Predible Healt Fujifilm Holdings Corporation Canon Medical Systems Hitachi Healthcare Vuno Inc. JLK Inspection 4DMedical HaloDoc AIHealth Ping An Good Doctor iFlytek HuiyiHuiying (HYHY) Ningbo Jansen NMR Technology Co., Ltd. YITU Technology Huawei Cloud Gleamer Guerbet Technologies Private Limited BioNTech SE Quantum Surgical Therapixel Merantix QUIBIM Nanobiosym Doctrin Icomera Sophia Genetics RetinAI Medical Eukarys Istituto Italiano di Tecnologia (IIT) Kheiron Medical Zaya AI Beeline Healbe Infermedica Syntellix AG Aireen CureMetrix Medo AI Caption Health DiA Imaging Analysis AI Precision Trillium Health Partners WELL Health Technologies Corp Stryker Corporation RadNet Beckman Coulter Diagnostics Exo Quest Diagnostics LabCorp Abbott Laboratories Thermo Fisher Scientific PathAI Diagnostics Bio-Rad Laboratories Becton Dickinson Agilent Technologies GenMark Diagnostics Butterfly Network Tempus AI Intel Corporation Micro Health LLC caption Health Inc. Dasha Coraline Soft Co Ltd. AI Medical Service Inc. International Business Machines Corp AliveCor, Inc. Digital Diagnostics Inc. Tamer Healthcare PureHealth Dell Technologies Astute Eyenuk, Inc. Dr CADx Envisionit Deep AI Ilara Health hearX Group Lancet Laboratories Dileny Technologies For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment AI in Medical Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Trump's tariffs cloud the future of a medical wonder
CORRECTION: A previous version of this article mistakenly identified Toshiba in Japan as a top manufacturer of CT scanners. Toshiba's medical subsidiary was acquired by the Japanese company Canon in 2016. Originally moved May 25. - - - Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. FORCHHEIM, Germany - On the outskirts of this bucolic town, in a region known as 'das Medical Valley,' workers on a vast factory floor are assembling what they describe as the future: the game-changing scanners that can give doctors the most detailed images ever of what is happening inside the hearts, lungs and brains of their patients. One of the scanners, two decades in the making and called the 'Naeotom Alpha,' is unique, say its inventors at Siemens Healthineers, a global leader in CT technology. 'The image quality is incomparable,' boasts Jesús Fernández, head of CT product marketing at the company, comparing the device's technological leap to the difference between a 1970s television set and HDTV. Since the scanners started shipping four years ago, leading hospitals around the world have ordered them. The Food and Drug Administration called the Naeotom Alpha - after approving its use - 'the first major new technology for computed tomography imaging in nearly a decade.' Forty percent of the scanners are exported to the U.S. market. Now Siemens Healthineers, other medical device makers and their customers are reckoning with a new challenge: the impact of President Donald Trump's global tariffs. The Trump disruption - the possible winners and losers, and the pure chaos - is roiling global manufacturers, from carmakers to champagne vignerons, as companies scramble to reassess their global trade partners and complex supply chains while trying to divine the president's next move. High-end medical devices, including those made by American manufacturers, may be especially vulnerable as many machines are built of components from a dozen vendors around the world. Some scanners cost millions of dollars and are so cutting-edge that hospitals publish a press release when they arrive. In early April, Trump targeted the European Union with a 20 percent levy. Days later, he paused those tariffs for 90 days, leaving a 10 percent across-the-board tax for most European imports, including medical equipment. The pause was set to end at the beginning of July. But on Friday, Trump threatened a 50 percent tariff on all goods from the E.U., beginning June 1, while complaining that trade negotiations with the bloc are 'going nowhere.' The medical tech industry - which produces everything from simple syringes to robot surgeons - has pleaded with Trump officials and members of Congress to exempt their products. The tariffs are too broad, recklessly so, critics say, arguing that a medical device is not like an automobile, but a thing vital for human health. Opposition to tariffs on medical devices hasn't come just from Europe, but from the United States, too. Competition in the CT scanner market is already fierce among top manufacturers, which include two American companies, GE and Philips, alongside Canon in Japan and Germany-based Siemens. Scott Whitaker, the CEO of AdvaMed, a prominent U.S. lobbying association for the sector, warned that Trump's threat of broad-based tariffs would act as an excise tax. 'It will have a negative impact on innovation, cost jobs, and increase overall costs to the health care system,' he said in a statement. 'Historically, industries with a meaningful humanitarian mission have been exempted from broad tariffs, and as a result we have seen no to low tariffs on med-tech from all key trading partners.' The Trump tariffs on medical equipment will not only cost foreign manufacturers but American companies, too. In an annual report to shareholders, GE HealthCare warned in April that U.S. tariffs imposed on products from China, along with any future levies on products from Canada, Mexico or other countries, 'will likely result in additional costs to us.' It was still too early to say whether the price of the Naeotom Alpha would be impacted. Siemens Healthineers warned earlier this month that tariffs and the 'significantly increased volatility of the geopolitical environment will weigh on our business this year.' As a result, the company lowered the midpoint of its projected earnings per share. On the call with analysts, Jochen Schmitz, the chief financial officer, said 'the biggest impact is imports in the U.S. from Europe.' Akin Demehin, vice president of quality and safety policy at the American Hospital Association, said tariffs could disrupt supplies of medical equipment and lead to higher costs. 'All CT scanners require some maintenance,' he said. 'To the extent that those get caught up in overseas supplies and tariffs impact their availability and price, that can potentially impact what the maintenance of those machines looks like,' he said. - - - A tool for saving lives In Germany, the Siemens Healthineers engineers describe their photon-counting CT scanner as a kind of medical wonder that can produce clearer, faster images for quicker diagnosis in a way that is less invasive for patients. It can help save lives, they say. Unlike conventional CT devices that measure the total energy contained in many X-rays at once, the Siemens devices deploy photon-counting detectors that capture each individual X-ray that passes through a patient's body, which results in more-detailed images. The typical patient can be scanned in just three seconds. The lower radiation compared with conventional CTs means the technology can also be used during pregnancies and on children and babies. Modern, conventional CT scanners primarily use solid-state crystal detectors made from a variety of materials. But for the photon-counting Naeotom model, Siemens Healthineers relies on cadmium telluride crystals, which the company now produces as well, including at the Forchheim plant. The intricacies of the process are kept tightly under wraps. In one room, identified as 'Kristallzüchtung,' or 'crystal growing,' fire in a tall black furnace emanates a soft glow. Inside, the synthesis of cadmium and tellurium that creates cadmium telluride is underway. 'Sometimes it feels a bit like alchemy,' said Paul Heimann, team lead of crystal growth. Siemens Healthineers is aiming for all its CTs to be photon-counting devices by 2040. Many in the industry will likely follow its path. Above the testing bays where the humming machines were being readied are star-spangled banners identifying the destination of both conventional and new photon-counting devices. 'U.S., U.S., U.S., U.S.,' points out David Engelstätter, head of CT production at the Forchheim plant. The Naeotom Alpha has already been purchased by several U.S. institutions, including the Mayo Clinic, New York University and Duke University, according to Siemens Healthineers. Some of the hospitals released jubilant press releases when the scanner was approved for use by the FDA. Asked to comment on the possible threat from tariffs, Duke said in a statement: 'We are always alert to market changes and are working to ensure we have the necessary equipment and supplies for optimal patient care.' NYU and Mayo declined to comment. Overall, the U.S. accounted for more than a quarter of Siemens Healthineers' business last year. Moving production, particularly of the unique photon-counting CTs, is out of the question, said Matthias Kraemer, head of corporate communications for Siemens Healthineers. It did not make business sense to have a lot of small factories churning out small numbers of devices, either in Germany or abroad, he said. 'We need that global scale.' The pioneers here in Bavaria say it is the patients who stand to suffer most from trade barriers. 'We all have family, friends, certainly sick friends or family members,' Engelstätter said on the shop floor. 'And then you think, what a shame it would be if I were in the U.S. right now and I were denied this screening - all due to external decisions.' - - - Tax policy, not tariffs In the United States, hospitals are bracing for the impact of tariffs. Higher costs would have to be absorbed, or passed along to insurers - including the U.S. government - and patients. Some 46 percent of hospitals expect that tariffs will increase facility costs in 2025, while an additional 42 percent said they anticipate higher costs when their contracts for supplies are renewed next year, according to a recent Bank of America survey of 50 chief financial officers at hospitals. Of the finance chiefs who responded, 91 percent expected costs to go up for medical equipment and devices. In reporting earnings last month, two major American firms that make medical devices - Johnson & Johnson and Abbott Laboratories - both estimated that tariffs would cost them a few hundred million dollars this year. But they also reaffirmed that they still expect to make about the same amount of money for the full year as they previously projected. Joaquin Duato, Johnson & Johnson's CEO, said that if the goal is to incentivize more manufacturing in the U.S. in both medical technology and pharmaceuticals, 'the most effective answer is not tariffs, but tax policy.' CT scanners range in cost from about $500,000 for entry-level machines to more than $3 million for the highest-end versions. The impact from tariffs could vary widely depending on their individual characteristics, such as where they are manufactured and what countries provide the key components, according to supply-chain experts. But it may take time for hospitals to directly feel the effects of tariffs. Hospitals may have multiyear contracts for machines, services and repairs, sparing them from immediate impacts, said Josh Hilton, senior director for diagnostic imaging and radiation oncology at Premier, Inc., which contracts with manufacturers to supply hospital customers. Still, the uncertainty of tariffs can influence hospital spending. 'When things like this happen, the purse strings tend to tighten up a little bit,' Hilton said. Instead of replacing an aging CT scanner this year, a hospital may push back the expenditure to next year, he said. Jesús Rueda Rodríguez, director general of industrial policy at MedTech Europe, which lobbies for European manufacturers, described complex supply chains. 'Components arrive through the United States, China, Europe,' meaning 'we can get hit by tariffs not once but multiple times.' The devices are highly regulated by health safety authorities, he said, as are the factories. As a result, 'you can't just pack up and move,' he said. Lukas Kratz - one of 5,000 employees at the Forchheim site - is a team leader, overseeing the assembly of the photon-counting CTs. Unlike in large-scale automobile factories, much of the work here is still done by hand. Now 29, he began working for Siemens a decade ago after completing his training as an electronics engineer. 'It's not just one device we're working on; we have many variants with many options,' he said. 'It's very difficult to show just anyone how to do this.' - - - Gilbert reported from Washington and Booth from London. Related Content Despite ceasefire, India and Pakistan are locked in a cultural cold war The D.C. plane crash took her mom and sister. She turned to her piano. Johnson again corrals GOP factions to pass Trump's sweeping tax bill
Yomiuri Shimbun
5 days ago
- Business
- Yomiuri Shimbun
Trump's Tariffs Cloud the Future of a Medical Wonder
Iona Dutz/For The Washington Post Lina Windfelder, a mechatronic engineer, at work at Siemens Healthineers in Forchheim. FORCHHEIM, Germany – On the outskirts of this bucolic town, in a region known as 'das Medical Valley,' workers on a vast factory floor are assembling what they describe as the future: the game-changing scanners that can give doctors the most detailed images ever of what is happening inside the hearts, lungs and brains of their patients. One of the scanners, two decades in the making and called the 'Naeotom Alpha,' is unique, say its inventors at Siemens Healthineers, a global leader in CT technology. 'The image quality is incomparable,' boasts Jesús Fernández, head of CT product marketing at the company, comparing the device's technological leap to the difference between a 1970s television set and HDTV. Since the scanners started shipping four years ago, leading hospitals around the world have ordered them. The Food and Drug Administration called the Naeotom Alpha – after approving its use – 'the first major new technology for computed tomography imaging in nearly a decade.' Forty percent of the scanners are exported to the U.S. market. Now Siemens Healthineers, other medical device makers and their customers are reckoning with a new challenge: the impact of President Donald Trump's global tariffs. The Trump disruption – the possible winners and losers, and the pure chaos – is roiling global manufacturers, from carmakers to champagne vignerons, as companies scramble to reassess their global trade partners and complex supply chains while trying to divine the president's next move. High-end medical devices, including those made by American manufacturers, may be especially vulnerable as many machines are built of components from a dozen vendors around the world. Some scanners cost millions of dollars and are so cutting-edge that hospitals publish a press release when they arrive. In early April, Trump targeted the European Union with a 20 percent levy. Days later, he paused those tariffs for 90 days, leaving a 10 percent across-the-board tax for most European imports, including medical equipment. The pause was set to end at the beginning of July. But on Friday, Trump threatened a 50 percent tariff on all goods from the E.U., beginning June 1, while complaining that trade negotiations with the bloc are 'going nowhere.' The medical tech industry – which produces everything from simple syringes to robot surgeons – has pleaded with Trump officials and members of Congress to exempt their products. The tariffs are too broad, recklessly so, critics say, arguing that a medical device is not like an automobile, but a thing vital for human health. Opposition to tariffs on medical devices hasn't come just from Europe, but from the United States, too. Competition in the CT scanner market is already fierce among top manufacturers, which include two American companies, GE and Philips, alongside Canon in Japan and Germany-based Siemens. Scott Whitaker, the CEO of AdvaMed, a prominent U.S. lobbying association for the sector, warned that Trump's threat of broad-based tariffs would act as an excise tax. 'It will have a negative impact on innovation, cost jobs, and increase overall costs to the health care system,' he said in a statement. 'Historically, industries with a meaningful humanitarian mission have been exempted from broad tariffs, and as a result we have seen no to low tariffs on med-tech from all key trading partners.' The Trump tariffs on medical equipment will not only cost foreign manufacturers but American companies, too. In an annual report to shareholders, GE HealthCare warned in April that U.S. tariffs imposed on products from China, along with any future levies on products from Canada, Mexico or other countries, 'will likely result in additional costs to us.' It was still too early to say whether the price of the Naeotom Alpha would be impacted. Siemens Healthineers warned earlier this month that tariffs and the 'significantly increased volatility of the geopolitical environment will weigh on our business this year.' As a result, the company lowered the midpoint of its projected earnings per share. On the call with analysts, Jochen Schmitz, the chief financial officer, said 'the biggest impact is imports in the U.S. from Europe.' Akin Demehin, vice president of quality and safety policy at the American Hospital Association, said tariffs could disrupt supplies of medical equipment and lead to higher costs. 'All CT scanners require some maintenance,' he said. 'To the extent that those get caught up in overseas supplies and tariffs impact their availability and price, that can potentially impact what the maintenance of those machines looks like,' he said. A tool for saving lives In Germany, the Siemens Healthineers engineers describe their photon-counting CT scanner as a kind of medical wonder that can produce clearer, faster images for quicker diagnosis in a way that is less invasive for patients. It can help save lives, they say. Unlike conventional CT devices that measure the total energy contained in many X-rays at once, the Siemens devices deploy photon-counting detectors that capture each individual X-ray that passes through a patient's body, which results in more-detailed images. The typical patient can be scanned in just three seconds. The lower radiation compared with conventional CTs means the technology can also be used during pregnancies and on children and babies. Modern, conventional CT scanners primarily use solid-state crystal detectors made from a variety of materials. But for the photon-counting Naeotom model, Siemens Healthineers relies on cadmium telluride crystals, which the company now produces as well, including at the Forchheim plant. The intricacies of the process are kept tightly under wraps. In one room, identified as 'Kristallzüchtung,' or 'crystal growing,' fire in a tall black furnace emanates a soft glow. Inside, the synthesis of cadmium and tellurium that creates cadmium telluride is underway. 'Sometimes it feels a bit like alchemy,' said Paul Heimann, team lead of crystal growth. Siemens Healthineers is aiming for all its CTs to be photon-counting devices by 2040. Many in the industry will likely follow its path. Above the testing bays where the humming machines were being readied are star-spangled banners identifying the destination of both conventional and new photon-counting devices. 'U.S., U.S., U.S., U.S.,' points out David Engelstätter, head of CT production at the Forchheim plant. The Naeotom Alpha has already been purchased by several U.S. institutions, including the Mayo Clinic, New York University and Duke University, according to Siemens Healthineers. Some of the hospitals released jubilant press releases when the scanner was approved for use by the FDA. Asked to comment on the possible threat from tariffs, Duke said in a statement: 'We are always alert to market changes and are working to ensure we have the necessary equipment and supplies for optimal patient care.' NYU and Mayo declined to comment. Overall, the U.S. accounted for more than a quarter of Siemens Healthineers' business last year. Moving production, particularly of the unique photon-counting CTs, is out of the question, said Matthias Kraemer, head of corporate communications for Siemens Healthineers. It did not make business sense to have a lot of small factories churning out small numbers of devices, either in Germany or abroad, he said. 'We need that global scale.' The pioneers here in Bavaria say it is the patients who stand to suffer most from trade barriers. 'We all have family, friends, certainly sick friends or family members,' Engelstätter said on the shop floor. 'And then you think, what a shame it would be if I were in the U.S. right now and I were denied this screening – all due to external decisions.' Tax policy, not tariffs In the United States, hospitals are bracing for the impact of tariffs. Higher costs would have to be absorbed, or passed along to insurers – including the U.S. government – and patients. Some 46 percent of hospitals expect that tariffs will increase facility costs in 2025, while an additional 42 percent said they anticipate higher costs when their contracts for supplies are renewed next year, according to a recent Bank of America survey of 50 chief financial officers at hospitals. Of the finance chiefs who responded, 91 percent expected costs to go up for medical equipment and devices. In reporting earnings last month, two major American firms that make medical devices – Johnson & Johnson and Abbott Laboratories – both estimated that tariffs would cost them a few hundred million dollars this year. But they also reaffirmed that they still expect to make about the same amount of money for the full year as they previously projected. Joaquin Duato, Johnson & Johnson's CEO, said that if the goal is to incentivize more manufacturing in the U.S. in both medical technology and pharmaceuticals, 'the most effective answer is not tariffs, but tax policy.' CT scanners range in cost from about $500,000 for entry-level machines to more than $3 million for the highest-end versions. The impact from tariffs could vary widely depending on their individual characteristics, such as where they are manufactured and what countries provide the key components, according to supply-chain experts. But it may take time for hospitals to directly feel the effects of tariffs. Hospitals may have multiyear contracts for machines, services and repairs, sparing them from immediate impacts, said Josh Hilton, senior director for diagnostic imaging and radiation oncology at Premier, Inc., which contracts with manufacturers to supply hospital customers. Still, the uncertainty of tariffs can influence hospital spending. 'When things like this happen, the purse strings tend to tighten up a little bit,' Hilton said. Instead of replacing an aging CT scanner this year, a hospital may push back the expenditure to next year, he said. Jesús Rueda Rodríguez, director general of industrial policy at MedTech Europe, which lobbies for European manufacturers, described complex supply chains. 'Components arrive through the United States, China, Europe,' meaning 'we can get hit by tariffs not once but multiple times.' The devices are highly regulated by health safety authorities, he said, as are the factories. As a result, 'you can't just pack up and move,' he said. Lukas Kratz – one of 5,000 employees at the Forchheim site – is a team leader, overseeing the assembly of the photon-counting CTs. Unlike in large-scale automobile factories, much of the work here is still done by hand. Now 29, he began working for Siemens a decade ago after completing his training as an electronics engineer. 'It's not just one device we're working on; we have many variants with many options,' he said. 'It's very difficult to show just anyone how to do this.'
Yahoo
6 days ago
- Business
- Yahoo
Digital Twins in Healthcare Market Research and Forecast Report 2025-2030: Europe Emerges as Key Player in Digital Twin Healthcare Market, Second to North America
The global digital twin healthcare market is set for remarkable growth, projected to soar from USD 4.47 billion in 2025 to USD 59.94 billion by 2030, at a CAGR of 68.0%. The surge is fueled by the expanding applications of digital twins in healthcare and increased investments from public and private sectors. Quibim, a Valencia-based pioneer using imaging biomarkers for precision medicine, recently raised USD 50.6 million in Series A funding to expand into the U.S. Market leaders like Microsoft, Siemens Healthineers, and GE Healthcare are advancing the sector. Notably, surgical planning & medical education, driven by virtual reality integration, captures the largest market share. Europe emerges as a key region, with substantial technological investments. The report offers a detailed analysis of market trends, competitive dynamics, and opportunities for growth in digital twin technology. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Digital Twins in Healthcare Market by Component (Software, Services), Application (Personalized Medicine, Drug Discovery, Medical Education, Workflow Optimization), End User (Providers, Research & Academia, Payers), and Region - Global Forecast to 2030" has been added to offering. The global digital twin healthcare market is poised for remarkable growth in 2024, driven by the expanding applications of digital twins and substantial investments from both public and private sectors. The market is expected to surge to USD 59.94 billion by 2030 from USD 4.47 billion in 2025, reflecting a CAGR of 68.0% during this period. Public and private sectors are keenly investing in digital twin technologies, recognizing their potential to revolutionize innovation and boost operational efficiency. Valencia-based Quibim is a leader in leveraging imaging biomarkers for precision medicine. Recently, Quibim secured USD 50.6 million in a Series A funding round aimed at establishing a foothold in the United States. This strategic move is seen as pivotal in advancing human digital twins, dynamic models that aid health monitoring, enhance patient stratification, increase drug development success rates, and enable pre-implementation treatment testing. By application, the surgical planning & medical education segment claimed the largest market share in 2024. The dominance of this segment is attributed to the fusion of digital twins with virtual reality platforms, significantly enhancing surgical training for residents. This technology allows for simulations tailored to individual patients' unique anatomical and physiological attributes, offering trainees a realistic experience and performance tracking through intraoperative metrics. Several companies have developed medical anatomy and surgical procedure simulations to reduce cadaver dependence and promote interactive learning. By end user, the healthcare providers segment commanded the largest market share in 2024. This segment's growth is linked to its critical role in workflow management and surgical planning. Digital twins provide benefits such as accurate patient modeling, personalized treatment planning, and continuous monitoring, all of which improve clinical decision-making and patient outcomes. Europe secured the second-largest market share in 2024 by region. This is due to increased technological investments and the application of digital twins in research and genomics. The European Institute of Innovation & Technology (EIT) Health Germany reports that digital twins are being employed across European nations to enhance medication prescriptions. French firm ExactCure specializes in digital health, focusing on preventing adverse drug effects. DigiTwins utilizes advanced omics, sensing, computing, and communication technologies, enabling completely personalized and preventive medicine, heralding a significant paradigm shift in healthcare. This report provides insights on: Drivers such as burgeoning investments in developed and emerging technology adoption, rising demand for personalized medicine, and increased funding and investment in digital twin startups. Restraints include concerns over accuracy and privacy in digital twin systems and high implementation costs. Opportunities and challenges are also examined. Product/Service Development & Innovation: Detailed insights into upcoming technologies, R&D activities, and new product and service launches. Market Development: Comprehensive data on lucrative emerging markets by type, component, application, end user, and region. Market Diversification: Information about product portfolios, expanding geographic reach, recent developments, and investments. Competitive Assessment: Thorough analysis of market shares, growth strategies, product offerings, and capabilities of leading players. Market Dynamics Market Drivers Increasing Investments by Public and Private Entities Growing Applications of Digital Twins Technological Advancements Growing Funding and Investments in Digital Twin Startups Challenges Lack of Skilled Professionals Integration With Existing Systems and Outdated Digital Infrastructure Industry Trends Transformation in Clinical Trials Revolutionizing Medical Training and Diagnostics Improving Operational Efficiency in Hospitals Opportunities Increasing Focus on Cutting-Edge Real-Time Data Analytics Growing Importance of Digital Twins in Emerging Economies Case Studies Utilization of Digital Twin Technology For Surge Planning Decisions Provision of Hospital Guidance Using Digital Twins in Healthcare During COVID-19 Pandemic Optimization of Cardiovascular Solutions For Personalized Treatments Company Profiles Microsoft Corporation Siemens Healthineers Ag Koninklijke Philips N.V. Amazon Web Services, Inc. Dassault Systemes Ge Healthcare Oracle Corporation IBM Ptc Sap Atos Se Nvidia Corporation Ansys Inc. Faststream Technologies Rescale, Inc. Twin Health Verto Qbio Thoughtwire Sim and Cure Predictiv Nurea Inc. Virtonomy Gmbh Predisurge For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
22-05-2025
- Health
- Globe and Mail
HIV Diagnosis Market to Hit USD 5.31 Billion by 2030 with 10.3% CAGR
"The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany)" Browse 332 market data Tables and 50 Figures spread through 273 Pages and in-depth TOC on "HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030 The global HIV diagnosis market, valued at US$2.96 billion in 2024, is forecasted to grow at a robust CAGR of 10.3%, reaching US$3.25 billion in 2025 and an impressive US$5.31 billion by 2030. The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent. Efforts driven by government health initiatives and public awareness campaigns promoting HIV testing are significantly boosting market growth. Additionally, innovations in testing technologies, such as rapid tests and self-testing kits, along with improved accuracy and ease of use, are enhancing patient compliance and encouraging wider adoption. Despite these positive developments, challenges like the high cost of diagnostic tests and complex testing procedures may slow down growth. However, the market is expected to continue progressing steadily, fueled by a stronger emphasis on early detection, improved healthcare access, and the increasing availability of advanced, convenient testing solutions. Browse in-depth TOC on " HIV Diagnosis Market" 332 - Tables 50 - Figures 273 - Pages Based on product type, the HIV diagnostics market is divided into consumables, instruments and software& services. In 2024, the consumables segment accounted for the largest share of the HIV diagnostics market. The large share and the high growth rate of the consumables segment can be attributed to the frequent & repetitive purchase of consumables by laboratories and hospitals; the growing prevalence of HIV/AIDS; and favorable government initiatives to launch advanced consumables in the market. Based on Test Type, the HIV diagnostics market is segmented into screening tests, confirmatory tests and monitoring tests. The monitoring tests segment accounted for the largest share of the HIV diagnostics market in 2024. This segment is also expected to grow at the highest CAGR owing to the increasing awareness of HIV testing; the high volume of monitoring test samples; and the growing establishment of diagnostic laboratories for testing of HIV/AIDS. Additional factors include technological advancements in monitoring testing kits. Based on end users, the HIV diagnostics market is segmented into diagnostic laboratories, hospitals, blood banks, home cares settings and other end users. The diagnostic laboratories segment accounted for the largest share of the HIV diagnostics market in 2024. The large share of this segment owed to the increasing prevalence of HIV/AIDS; the rising establishment of diagnostic laboratories; growing sample testing; and advancements in PoC instruments. The HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominates the global market and is expected to continue during the forecast period. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North America. However, the Asia Pacific market is expected to grow at the highest CAGR of 12.5% during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this region. The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others. ABBOTT (US) Abbott is the leading player in the HIV diagnostics market. The company has a strong presence in the US and seeks to enhance its geographical presence by strengthening its business operations in emerging markets. The company has a strong product portfolio, and its FDA- and CE-approved products have helped it gain a sizable market share. Abbott focuses on inorganic growth strategies, such as collaborations and acquisitions, to enhance its product portfolio and expand its geographical presence. The company's extensive research & development activities for product development and its ongoing clinical trials for newly developed products will further enhance its share in the HIV diagnostics market. SIEMENS HEALTHINEERS AG (GERMANY) Siemens Healthineers AG is among the leading players in the global HIV diagnostics market. The company provides a comprehensive portfolio of medical solutions, from medical imaging and in vitro diagnostics to interventional and clinical information technology systems. The company focuses on organic strategies, including product approvals, to enhance its presence in the global POC market. It also aims to create innovative products that address the unmet needs of patients and healthcare providers and take the first-mover advantage. The company also focuses on partnerships and collaborations to enhance its market presence. For instance, in December 2023, Siemens Healthineers AG and OU Health entered a 10-year value partnership to bring the latest diagnostic and therapeutic equipment to people across Oklahoma. THERMO FISHER SCIENTIFIC (US) Thermo Fisher Scientific is a key player in the global HIV diagnostics market, offering a comprehensive range of diagnostic solutions, including PCR-based assays, immunoassays, and molecular testing technologies. The company has a strong presence in developed and emerging markets, leveraging its advanced research capabilities and extensive distribution network. Thermo Fisher focuses on continuous innovation, regulatory approvals, and strategic acquisitions to expand its product portfolio. Additionally, the company collaborates with healthcare organizations and government agencies to enhance diagnostic accessibility and improve early detection of HIV. For more information, Inquire Now!
